Journal of Ophthalmic and Optometric Sciences

Vol. 9 No. 1 (2025)

Effectiveness of Intravitreal Bevacizumab for Diabetic Macular Edema in Eyes with Preserved Visual Acuity: A Prospective Clinical Trial

Journal of Ophthalmic and Optometric Sciences, Vol. 9 No. 1 (2025), 21 December 2024 , Page 8-16
https://doi.org/10.22037/joos.v9i1.49717

Abstract

Purpose: To assess the effectiveness of intravitreal Bevacizumab injections in reducing central macular thickness and preserving visual acuity in diabetic patients with center-involving macular edema and good baseline vision.
Patients and Methods: This prospective clinical trial was conducted over 18 months starting in April 2017. Patients with non-proliferative diabetic retinopathy, visual acuity ≥20/25, and central macular thickness > 300 µm on OCT were included. Participants were assigned to two groups: one received intravitreal Bevacizumab (1.2 mg), and the other was monitored without treatment. Central macular thickness and best-corrected visual acuity were measured at baseline and six months postoperatively.
Results: Twenty-two eyes completed the study (12 treated, 10 control). In the treatment group, the mean macular thickness decreased from 319 µm to 301 µm (P = 0.031). In the control group, it increased from 318 µm to 328 µm. However, the intergroup difference at six months was not statistically significant (P = 0.581). Visual acuity declined slightly in both groups: from 9.05/10 to 8.7/10 in the treated group and from 9.3/10 to 9.2/10 in controls, with no significant difference between groups (P = 0.373). No adverse events were reported.
Conclusion: Bevacizumab injections led to a modest reduction in macular thickness but did not significantly improve or preserve visual acuity in diabetic patients with good baseline vision. These findings suggest that factors beyond vascular endothelial growth factor may play a role in early-stage diabetic macular edema. Further studies with a higher sample size are suggested to confirm our findings.

Keywords:
  • Diabetic Macular Edema
  • Bevacizumab
  • Anti-VEGF
  • Visual Acuity
  • OCT

How to Cite

Daryabari, S. H., Hassani , M., & Alishiri , A. (2024). Effectiveness of Intravitreal Bevacizumab for Diabetic Macular Edema in Eyes with Preserved Visual Acuity: A Prospective Clinical Trial. Journal of Ophthalmic and Optometric Sciences, 9(1), 8–16. https://doi.org/10.22037/joos.v9i1.49717

References

- Kropp M, Golubnitschaja O, Mazurakova A, Koklesova L, Sargheini N, Vo TKS, et al. Diabetic retinopathy as the leading cause of blindness and early predictor of cascading complications-risks and mitigation. EPMA J. 2023;14(1):21-42.

- Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015;2:17.

- Romero-Aroca P. Managing diabetic macular edema: The leading cause of diabetes blindness. World J Diabetes. 2011;2(6):98-104.

- Wong TY, Sun J, Kawasaki R, Ruamviboonsuk P, Gupta N, Lansingh VC, et al. Guidelines on Diabetic Eye Care: The International Council of Ophthalmology Recommendations for Screening, Follow-up, Referral, and Treatment Based on Resource Settings. Ophthalmology. 2018;125(10):1608-22.

- Musat O, Cernat C, Labib M, Gheorghe A, Toma O, Zamfir M, et al. Diabetic Macular Edema. Rom J Ophthalmol. 2015;59(3):133-6.

- Browning DJ, Stewart MW, Lee C. Diabetic macular edema: Evidence-based management. Indian J Ophthalmol. 2018;66(12):1736-50.

- Edington M, Sachdev A, Morjaria R, Chong V. Structural-Functional Correlation in Patients with Diabetic Macular Edema. Retina. 2017;37(5):881-5.

- Vinores SA. Breakdown of the Blood–Retinal Barrier. Encyclopedia of the Eye. 2010:216-22.

- Ford JA, Lois N, Royle P, Clar C, Shyangdan D, Waugh N. Current treatments in diabetic macular oedema: systematic review and meta-analysis. BMJ Open. 2013;3(3):e002269.

- Midena E, Segato T, Bottin G, Piermarocchi S, Fregona I. The effect on the macular function of laser photocoagulation for diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 1992;230(2):162-5.

- Hui VWK, Szeto SKH, Tang F, Yang D, Chen H, Lai TYY, et al. Optical Coherence Tomography Classification Systems for Diabetic Macular Edema and Their Associations With Visual Outcome and Treatment Responses - An Updated Review. Asia Pac J Ophthalmol (Phila). 2022;11(3):247-57.

- Bhende M, Shetty S, Parthasarathy MK, Ramya S. Optical coherence tomography: A guide to interpretation of common macular diseases. Indian J Ophthalmol. 2018;66(1):20-35.

- Im JHB, Jin YP, Chow R, Yan P. Prevalence of diabetic macular edema based on optical coherence tomography in people with diabetes: A systematic review and meta-analysis. Surv Ophthalmol. 2022;67(4):1244-51.

- Furino C, Boscia F, Reibaldi M, Alessio G. Intravitreal Therapy for Diabetic Macular Edema: An Update. J Ophthalmol. 2021;2021:6654168.

- Mehta H, Gabrielle PH, Hashimoto Y, Kibret GD, Arnold J, Guillaumie T, et al. One-Year Anti-VEGF Therapy Outcomes in Diabetic Macular Edema Based on Treatment Intensity: Data from the Fight Retinal Blindness! Registry. Ophthalmol Retina. 2024;8(9):872-9.

- Aldokhail LS, Alhadlaq AM, Alaradi LM, Alaradi LM, AlShaikh FY. Outcomes of Anti-VEGF Therapy in Eyes with Diabetic Macular Edema, Vein Occlusion-Related Macular Edema, and Neovascular Age-Related Macular Degeneration: A Systematic Review. Clin Ophthalmol. 2024;18:3837-51.

- Gurung RL, FitzGerald LM, Liu E, McComish BJ, Kaidonis G, Ridge B, et al. Predictive factors for treatment outcomes with intravitreal anti-vascular endothelial growth factor injections in diabetic macular edema in clinical practice. Int J Retina Vitreous. 2023;9(1):23.

- Sharma D, Zachary I, Jia H. Mechanisms of Acquired Resistance to Anti-VEGF Therapy for Neovascular Eye Diseases. Invest Ophthalmol Vis Sci. 2023;64(5):28.

- Owen LA, Hartnett ME. Soluble mediators of diabetic macular edema: the diagnostic role of aqueous VEGF and cytokine levels in diabetic macular edema. Curr Diab Rep. 2013;13(4):476-80.

- Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, et al. Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA). Ophthalmologica. 2017;237(4):185-222.

- Virgili G, Parravano M, Menchini F, Evans JR. Anti-vascular endothelial growth factor for diabetic macular oedema. Cochrane Database Syst Rev. 2014;(10):CD007419.

- Stefanini FR, Arevalo JF, Maia M. Bevacizumab for the management of diabetic macular edema. World J Diabetes. 2013;4(2):19-26.

- Diabetic Retinopathy Clinical Research Network; Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064-77.

- Dugel PU, Hillenkamp J, Sivaprasad S, Vögeler J, Mousseau MC, Wenzel A, et al. Baseline visual acuity strongly predicts visual acuity gain in patients with diabetic macular edema following anti-vascular endothelial growth factor treatment across trials. Clin Ophthalmol. 2016;10:1103-10.

- Sharma S, Daigavane S, Shinde P. Innovations in Diabetic Macular Edema Management: A Comprehensive Review of Automated Quantification and Anti-vascular Endothelial Growth Factor Intervention. Cureus. 2024;16(2):e54752.

- Zhang X, Zeng H, Bao S, Wang N, Gillies MC. Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci. 2014;4:27.

- Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges R. Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory. J Diabetes Res. 2016;2016:2156273.

- Markan A, Agarwal A, Arora A, Bazgain K, Rana V, Gupta V. Novel imaging biomarkers in diabetic retinopathy and diabetic macular edema. Ther Adv Ophthalmol. 2020;12:2515841420950513.

- Joltikov KA, Sesi CA, de Castro VM, Davila JR, Anand R, Khan SM, et al. Disorganization of Retinal Inner Layers (DRIL) and Neuroretinal Dysfunction in Early Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2018;59(13):5481-6.

- Sakini ASA, Hamid AK, Alkhuzaie ZA, Al-Aish ST, Al-Zubaidi S, Tayem AA, et al. Diabetic macular edema (DME): dissecting pathogenesis, prognostication, diagnostic modalities along with current and futuristic therapeutic insights. Int J Retina Vitreous. 2024;10(1):83.

- Ţălu Ş, Nicoara SD. Malfunction of outer retinal barrier and choroid in the occurrence and progression of diabetic macular edema. World J Diabetes. 2021;12(4):437-52.

- Shen J, Frye M, Lee BL, Reinardy JL, McClung JM, Ding K, et al. Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature. J Clin Invest. 2014;124(10):4564-76.

- Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA. Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease. Expert Opin Investig Drugs. 2019;28(10):861-9.

- Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology. 1991;98(5):741-56.

- Gao X, Obeid A, Aderman CM, Talcott KE, Ali FS, Adam MK, et al. Loss to Follow-up After Intravitreal Anti-Vascular Endothelial Growth Factor Injections in Patients with Diabetic Macular Edema. Ophthalmol Retina. 2019;3(3):230-6.

  • Abstract Viewed: 48 times
  • pdf Downloaded: 100 times

Download Statastics

Current Issue